• Anixa Biosciences will present at the Nasdaq & LD Micro Inaugural SF Summit on Sept. 9, 2026.
• Talk scheduled for 3:40 PM PT at Nasdaq’s San Francisco headquarters, followed by a breakout session.
• Update expected on its Phase 1 CAR-T program in ovarian cancer, run with Moffitt Cancer Center, with no dose-limiting toxicities reported.
• Discussion to cover its Phase 1 breast cancer vaccine trial at Cleveland Clinic, funded by the U.S. Department of Defense, which met primary endpoints.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609030800PR_NEWS_USPR_____LA39931) on September 03, 2026, and is solely responsible for the information contained therein.